<?xml version="1.0" encoding="UTF-8"?><feed xmlns="http://www.w3.org/2005/Atom">
  <title>药事纵横 | wechat-feeds</title>
  <id>https://github.com/hellodword/wechat-feeds</id>
  <updated>2021-01-07T11:51:15+08:00</updated>
  <subtitle>药事纵横是一个由多位制药精英联合创办的媒体平台，旨在分享与传递药品研发、生产和注册中所涉及的技术、经验和情报，欢迎关注和投稿！投稿请发442015666@qq.com</subtitle>
  <link href="https://github.com/hellodword/wechat-feeds"></link>
  <author>
    <name>hellodword</name>
  </author>
  <entry>
    <title>辉瑞：现代药品销售的缔造者和并购交易的集大成者</title>
    <updated>2021-01-07T09:03:22+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-07:/s/aZKkqsEez7pTc303rfXh1A</id>
    <link href="https://mp.weixin.qq.com/s/aZKkqsEez7pTc303rfXh1A" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>中国企获得的近700个ANDA批文汇总，包括2020年的93个</title>
    <updated>2021-01-07T09:03:22+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-07:/s/hhRndxkKXX7jnv9VLMKxXQ</id>
    <link href="https://mp.weixin.qq.com/s/hhRndxkKXX7jnv9VLMKxXQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>年底高峰：86个新批文、181个过评价 | 12月仿制药动态</title>
    <updated>2021-01-07T09:03:22+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-07:/s/v_byJ85FQg2bwV1aadH4XA</id>
    <link href="https://mp.weixin.qq.com/s/v_byJ85FQg2bwV1aadH4XA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>Medicines公司发家故事：临床失败项目巧妙二次复活，变废为宝，铸就成功</title>
    <updated>2021-01-05T22:26:29+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-05:/s/6ONeDiuIwsIITwgi-rIXfg</id>
    <link href="https://mp.weixin.qq.com/s/6ONeDiuIwsIITwgi-rIXfg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【美国已完成2期】国外新药寻找合作伙伴</title>
    <updated>2021-01-05T22:26:29+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-05:/s/gKfE9oKSVqAnUPjHq88t1A</id>
    <link href="https://mp.weixin.qq.com/s/gKfE9oKSVqAnUPjHq88t1A" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>2020年医药政策的13大核心内容、5点建议</title>
    <updated>2021-01-05T22:26:29+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-05:/s/pYiT-G0ZqSOmrZWoSeo8Hw</id>
    <link href="https://mp.weixin.qq.com/s/pYiT-G0ZqSOmrZWoSeo8Hw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【分享】没有业绩的我，今年如何写年终总结？</title>
    <updated>2021-01-05T22:26:29+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-05:/s/aqmO1NXWMY8shT2hgk9L6Q</id>
    <link href="https://mp.weixin.qq.com/s/aqmO1NXWMY8shT2hgk9L6Q" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>体外溶出与体内不相关？试试流通池法溶出</title>
    <updated>2021-01-04T20:26:14+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-04:/s/rJ395GpVa3PggALqg5BlSA</id>
    <link href="https://mp.weixin.qq.com/s/rJ395GpVa3PggALqg5BlSA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>邀请函 | 临床开发与创新合作论坛 2021</title>
    <updated>2021-01-04T20:26:14+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-04:/s/Gqfp2nDYQ-rUnBsLRdHz6g</id>
    <link href="https://mp.weixin.qq.com/s/Gqfp2nDYQ-rUnBsLRdHz6g" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>几张图了解单抗市场的变化</title>
    <updated>2021-01-04T20:26:14+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-04:/s/r6xXlvymbj41SFOhrFPUqw</id>
    <link href="https://mp.weixin.qq.com/s/r6xXlvymbj41SFOhrFPUqw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>职场中无处不在的知识垄断</title>
    <updated>2021-01-04T20:26:14+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-04:/s/fvHqyLcvdU6wl4J-klfZ9g</id>
    <link href="https://mp.weixin.qq.com/s/fvHqyLcvdU6wl4J-klfZ9g" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>2020年最值得关注的“重磅炸弹”级新药</title>
    <updated>2021-01-04T11:52:16+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-04:/s/6SqIGkJRocnewEHe9qSMyQ</id>
    <link href="https://mp.weixin.qq.com/s/6SqIGkJRocnewEHe9qSMyQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>再极医药完成近2亿元人民币的C轮融资，优选资本领投</title>
    <updated>2021-01-04T11:52:16+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-04:/s/nt8PnEHe5aXjiPYYJKXoBQ</id>
    <link href="https://mp.weixin.qq.com/s/nt8PnEHe5aXjiPYYJKXoBQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>压片合格，总混含量却不合格，为什么？</title>
    <updated>2021-01-04T11:52:16+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-04:/s/JIu-5ywMll7nC9XsE9unEQ</id>
    <link href="https://mp.weixin.qq.com/s/JIu-5ywMll7nC9XsE9unEQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>年终大总结：我眼中值得提一嘴的新批改良新药</title>
    <updated>2021-01-03T14:55:59+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-03:/s/0-vPyHDbC9nNbfehZAPb0A</id>
    <link href="https://mp.weixin.qq.com/s/0-vPyHDbC9nNbfehZAPb0A" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>2020年EMA和PMDA率先批准上市的18个新药逐个评述</title>
    <updated>2021-01-02T11:10:08+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-02:/s/r8vGmMBGB95UDPXr-oojdQ</id>
    <link href="https://mp.weixin.qq.com/s/r8vGmMBGB95UDPXr-oojdQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>新公众号“药海书香”，期待各位大佬的关注</title>
    <updated>2021-01-02T11:10:08+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-02:/s/oW8NyJzQOsk901kzbMxVvg</id>
    <link href="https://mp.weixin.qq.com/s/oW8NyJzQOsk901kzbMxVvg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>创新药年终总结：2020年NMPA批准的13个1类新药逐个评述</title>
    <updated>2021-01-01T11:34:27+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-01:/s/sOdplmTnSVgrVDxZqkcd-g</id>
    <link href="https://mp.weixin.qq.com/s/sOdplmTnSVgrVDxZqkcd-g" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>FDA批准药物的全景分析（二）：复杂制剂及制剂未来</title>
    <updated>2020-12-31T05:55:51+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-31:/s/J0EhjNacmqNwfq0iS0opRA</id>
    <link href="https://mp.weixin.qq.com/s/J0EhjNacmqNwfq0iS0opRA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>NMPA批准和记黄埔的索凡替尼用于神经内分泌瘤治疗</title>
    <updated>2020-12-31T05:55:51+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-31:/s/Mu356o9k4faGSxss_20iwA</id>
    <link href="https://mp.weixin.qq.com/s/Mu356o9k4faGSxss_20iwA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
</feed>